# Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer

> **NCT05851365** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Robert Flavell, MD, PhD** · enrollment: 1 (actual)

## Conditions studied

- Prostate Cancer
- Localized Prostate Carcinoma

## Interventions

- **DRUG:** Hyperpolarized Bicarbonate (13C)
- **PROCEDURE:** Magnetic Resonance imaging

## Key facts

- **NCT ID:** NCT05851365
- **Lead sponsor:** Robert Flavell, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-06
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05851365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05851365, "Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05851365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*